Clinical Trial Update: Positron Emission Tomography/Computed Tomography (PET/CT) Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-4367 in Patients With Prostate Cancer and Healthy Volunteers [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating BAY86-4367 for PET/CT imaging, pharmacokinetics, biodistribution, safety, and diagnostic performance in prostate cancer patients and he…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• BAY86-4367 (BAY86-4367)

Snippet

Sponsor: Bayer | Conditions: Diagnostic Imaging | Phase 1 | Status: TERMINATED